Bioequivalence Study of Atenolol Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1414 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Yongtao Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Adrenergic beta-1 Receptor Antagonists, Atenolol. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Atenolol, a cardioselective β1‐blocker, exhibits efficacy in treating cardiovascular diseases. We conducted a single‐center, randomized, open, single‐dose, 2‐preparation, 2‐cycle, 2‐sequence, double‐crossover trial with a 7‐day washout period to investigate the pharmacokinetics, bioequivalence (BE), and safety of test and reference atenolol tablets (25 mg) in healthy Chinese volunteers. Forty‐eight healthy participants were randomized into the fasting and fed arms. After administering a single oral dose of the test or reference formulation (25 mg), plasma atenolol concentrations were measured using liquid chromatography‐tandem mass spectrometry. Pharmacokinetic parameters were obtained from concentration‐time profiles. In total, 23 and 24 individuals were included in the fasting and fed arms, respectively. The mean concentration‐time profiles for both formulations were similar, and C max , AUC 0‐t , and AUC 0‐∞ were within the BE range of 80%‐125%. Thirteen adverse events (AEs) were observed in 7 participants in the fasting arm; 1 withdrew from the trial early owing to an AE. In the fed arm, 20 AEs were observed in 8 participants, and none withdrew from the trial. All adverse reactions were grade I, with no serious AEs or deaths. Therefore, the 2 tablets are bioequivalent in healthy Chinese individuals under fasting and fed conditions, supporting their further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China.
- Infection Medicine Research Institute of Panyu District, Guangzhou, China.
- College of Pharmacy, Jinan University, Guangzhou, China.
Zitieren
APA
Li, Y., Huang, Y., Fu, X., Xia, J., Su, J., Gu, W., Liu, W., Jian, J., & Xu, Z. (2024). Bioequivalence Study of Atenolol Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1414
Vancouver
Li Y, Huang Y, Fu X, Xia J, Su J, Gu W, et al. Bioequivalence Study of Atenolol Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1414
BibTeX
@article{Li2024,
author = {Li, Yongtao and Huang, Yingying and Fu, Xihua and Xia, Jiajing and Su, Jianfen and Gu, Wenzhao and Liu, Weixiong and Jian, Jianqing and Xu, Zuoheng},
title = {Bioequivalence Study of Atenolol Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1414}
}
EUVIMED